文献速递妇科

子宫内膜癌分子亚型分型的预算影响分析

Budget impact analysis of molecular subtype profiling in endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2023-10-02

本研究从医院视角评估子宫内膜癌四种分型方法(组织形态学、组织形态学联合免疫组化、组织分子分型、选择性分子分型)的直接成本,并进行预算影响分析和敏感性分析,以2022年加拿大元报告每样本成本及年度机构成本。2018年本机构完成190例子宫内膜癌活检,组织形态学、联合免疫组化、组织分子分型的每例平均成本分别为158加元、384加元、1297加元。作者指出,鉴于这些方法带来的医疗成本显著增加,临床实践中实施分子分型需知情决策。

要点

  • 组织形态学分型每例平均成本158加元,联合免疫组化为384加元,组织分子分型为1297加元。
  • 组织分子分型首年机构成本246521加元,后续每年233461加元(假设活检数量稳定)。
  • 对高级别、p53异常和/或MMR缺陷的子宫内膜癌(占56%)选择性实施组织分子分型,首年成本169688加元,后续每年162418加元。

核心结论

  • 鉴于分子分型相关医疗成本显著增加,临床实践中实施分子分型需知情决策。

研究设计与样本

  • 从医院视角确定每例子宫内膜癌样本的直接成本,并进行预算影响分析和敏感性分析,以2022年加拿大元报告每样本平均、最低和最高成本及年度机构成本。
  • 基于2022年预计子宫内膜癌活检数量预测省级成本。

主要发现

  • 2018年本机构完成190例子宫内膜癌活检,组织形态学分类每例平均成本158加元(范围156-212加元)。
  • 组织形态学联合免疫组化每例平均成本384加元(范围360-514加元),组织分子分型每例平均成本1297加元(范围1265-1833加元)。
  • 组织形态学分类年度总机构成本为29980加元,联合免疫组化为72950加元;组织分子分型首年成本246521加元(含初始教育学习曲线),后续每年233461加元(假设每年活检数量稳定)。
  • 对高级别、p53异常和/或MMR缺陷的子宫内膜癌(占56%)选择性实施组织分子分型,首年成本169688加元,后续每年162418加元。
  • 2022年安大略省预计3400例子宫内膜癌活检,组织形态学分类年度成本537078加元,联合免疫组化为1305677加元;组织分子分型首年成本4410203加元,建立后每年4176737加元;选择性分子分型首年成本3044178加元,后续每年2913443加元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study evaluated the costs associated with four approaches to classifying endometrial cancer (EC), including histomorphological, histomorphological with ancillary immunohistochemical assays, histomolecular and selective molecular classification. METHODS: Direct costs were determined per EC sample from the hospital's perspective. A budget impact analysis and sensitivity analysis were conducted to estimate the mean, minimum and maximum costs per sample and annual institutional costs in adjusted 2022 Canadian dollars. A provincial cost forecast was projected based on expected 2022 EC biopsies. RESULTS: In 2018, our institution performed 190 EC biopsies. The mean cost per biopsy was $158 ($156-$212) for histomorphological classification, $384 ($360-$514) for histomorphological classification with immunohistochemistry and $1297 ($1265-1833) for histomolecular classification. Total annual institutional cost for histomorphological classification was $29,980 and $72,950 with immunohistochemistry. For histomolecular classification, the first year cost was $246,521, accounting for initial educational learning curve, and $233,461 thereafter, assuming a consistent number of biopsies per year. Targeted implementation of histomolecular classification among high-grade, p53 abnormal and/or MMR-deficient ECs (56% of cases) cost $169,688 in the first year and $162,418 annually thereafter. With a projected 3400 EC biopsies in Ontario in 2022, histomorphological classification would annually cost $537,078 and $1,305,677 with immunohistochemistry. Histomolecular classification would cost $4,410,203 in the first year and $4,176,737 annually once established. Selective molecular classification would lead to a cost of $3,044,178 in the first year and $2,913,443 thereafter. CONCLUSIONS: The study highlights the need for informed decision-making when implementing molecular classification in clinical practice, given the substantial incremental healthcare costs associated with these approaches.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Plotkin A, Olkhov-Mitsel E, Nofech-Mozes S, et al. Budget impact analysis of molecular subtype profiling in endometrial cancer. Gynecol Oncol. 2023. PMID: 37793305. doi:10.1016/j.ygyno.2023.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。